The road to find an effective treatment for Alzheimer’s has been long and tortured. Established industry titans have spent many years developing promising drugs, only to see them fail in late-stage trials.

NeuroTherapia Inc., a Cleveland Clinic spinoff, is trying a new approach. Instead of targeting the amyloid plaques thought to contribute to Alzheimer’s disease, NeuroTherapia is focusing on the role of microglia, cells within the central nervous system that cause uncontrolled inflammation.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for our biotech newsletter, The Readout

Get our guide to what's new in biotech delivered each morning.

Recommended Stories